Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
38.37
-0.32 (-0.83%)
Jan 31, 2025, 4:00 PM EST - Market closed
Supernus Pharmaceuticals Employees
Supernus Pharmaceuticals had 652 employees as of December 31, 2023. The number of employees increased by 40 or 6.54% compared to the previous year.
Employees
652
Change (1Y)
40
Growth (1Y)
6.54%
Revenue / Employee
$999,957
Profits / Employee
$91,583
Market Cap
2.12B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
SUPN News
- 6 weeks ago - Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada - GlobeNewsWire
- 2 months ago - Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth - Seeking Alpha
- 3 months ago - Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - GlobeNewsWire
- 3 months ago - Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder - GlobeNewsWire